Six5 inhibitors are a specialized category of chemical compounds that predominantly focus on modulating the activity of the Six5 gene. This gene, a component of the homeobox gene family, plays a critical role in the regulation and coordination of developmental processes within organisms. Inhibitors targeting Six5 function to intervene in the gene's expression or the protein's activity, thereby manipulating the cellular and molecular pathways that are orchestrated by Six5. By doing so, these inhibitors can provide valuable insights into the understanding of developmental biology, cellular differentiation, and various physiological processes. Additionally, the innovative chemical architecture of Six5 inhibitors allows for the exploration of the molecular mechanisms through which the Six5 gene exerts its influence, paving the way for refined biochemical knowledge and the elucidation of complex biological networks and systems.
The design and synthesis of Six5 inhibitors entail meticulous chemical expertise, ensuring specificity and effectiveness in modulating the target gene. These compounds are often evaluated based on their ability to bind to the active sites, influence transcriptional activities, and alter protein interactions associated with the Six5 gene. Scientific exploration involving Six5 inhibitors facilitates profound explorations into genetic regulation, contributing to a more comprehensive understanding of genetic orchestration in biological systems. Thus, Six5 inhibitors serve as powerful tools in molecular biology and genetic research, opening avenues for the study of gene functions and interactions in intricate biological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits tyrosine kinase activity of BCR-ABL fusion protein, used for chronic myeloid leukemia (CML). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Blocks multiple kinases, including Raf and VEGFR, suppressing tumor cell proliferation and angiogenesis in advanced cancers. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, reducing cell growth and division in lung and pancreatic cancers. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2 kinases, impeding signal transduction and growth in breast cancer cells. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets EGFR kinase domain, blocking cell signaling pathways, and is used in non-small cell lung cancer (NSCLC). | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits BCR-ABL and Src family kinases, affecting CML and Ph+ ALL, by blocking cancer cell proliferation and survival. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Specifically inhibits BRAF kinase with the V600E mutation, used in melanoma therapy by blocking abnormal cell growth. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly binds to BTK, impeding B-cell signaling and used for B-cell malignancies like CLL and mantle cell lymphoma. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Targets JAK1 and JAK2 kinases, reducing cytokine-mediated inflammation | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Inhibits CDK4 and CDK6, regulating cell cycle progression, and is used for HR-positive, HER2-negative breast cancer therapy. | ||||||